Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7552W HIGH $32.96
Volume
543.34 K
Value Traded
151.93 K
Short % Float
6.3%
Days to Cover
2.0
-1.7%Week
-27.59%1 Month
-58.93%3 Month
-84.71%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.08 M
EPS (TTM)
-4.53
P/E Ratio
-
Ent. Value
-2.34 M
Total Shares
2.52 M
Float Shares
2.52 M
Insiders
0.00%
Institutions
2.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ISPC Catalyst Timeline
Dated clinical, regulatory and corporate events for iSpecimen Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for iSpecimen Inc.
43Total events
0Upcoming
0Tier-1 (high impact)
2021 to 2026Coverage
Event history 43
▼Equity OfferingCorporate
Closing of $5 million public offering of common stock and pre-funded warrants
▼Equity OfferingCorporate
Pricing of approximately $1.75 million private placement at $1.122 per share
▼Equity OfferingCorporate
Pricing of $5 million public offering of common stock and pre-funded warrants
◆ATM ProgramCorporate
iSpecimen enters into At the Market Offering Agreement for up to $1.5 million
▲Quarterly UpdateCorporate
Preliminary Q3 2023 revenue of $2.6-$2.8 million (60-70% sequential increase)
▼Equity OfferingCorporate
Closed private placement of common stock and warrants for ~$21M gross proceeds
Past FDA Catalysts and PDUFA Decisions
How ISPC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ISPC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bielak BenjaminOfficer (Chief Info Officer & Secretary) | Buy | 18,000 84,348 held | $0.72 | 09/14/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in ISPC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ISPC for Q2 2026. | ||||
ISPC Institutional Ownership Trends
ISPC Short Interest
Shares sold short, counted twice a month.
6.3%
Short % of Float
of tradable shares sold short
158.8K
Shares Sold Short
-1.4% vs prior count
2.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
79.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ISPC ranks across every disease it competes in
Competitive Position is a premium feature
See how ISPC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialISPC News
-ISPC
Aug 20, 2026▼ -25.6%on this news
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
iSpecimen has successfully completed a large-scale international cancer research order, shipping hundreds of blood specimens within three weeks. This achievement highlights the company's efficient biospecimen sourcing and fulfillment capabilities. The project involved extensive coordination with healthcare and research partners, showcasing iSpecimen's commitment to supporting timely medical research. CEO Ms. Field noted the critical nature of prompt specimen delivery for advancing research.
Read more →-ISPC
Aug 7, 2026iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
iSpecimen Inc. has successfully closed a public offering, raising approximately $5 million through the sale of common stock and pre-funded warrants. The company plans to utilize the proceeds for repaying liabilities, potential acquisitions, and marketing efforts. The offering was facilitated by E.F. Hutton & Co. and is part of a registration statement filed with the SEC.
Read more →-ISPC
Aug 6, 2026▲ +14.6%on this newsshared move
iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
iSpecimen Inc. has announced the pricing of a public offering of approximately $5 million in common stock and pre-funded warrants at a price of $1.30 per share. The proceeds will be allocated towards repaying liabilities, potential acquisitions, and marketing efforts. The offering is expected to close on August 7, 2026, pending customary conditions.
Read more →-ISPC
May 9, 2026iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
iSpecimen Inc. has announced a private placement offering priced at approximately $2.5 million, set to close around May 11, 2026. The company will issue 488,281 shares at $5.12 each, with options for pre-funded warrants. Proceeds will be used for working capital, including marketing expenses. The offering is subject to stockholder approval for additional share issuance.
Read more →-ISPC
Apr 24, 2026▼ -19.6%on this news· ran to -34% by day 3
iSpecimen Announces 1-for-40 Reverse Stock Split
iSpecimen announced a 1-for-40 reverse stock split of its common stock, effective April 27, 2026, to raise its trading price and attract institutional investors. This decision follows the approval of stockholders and aims to comply with Nasdaq's minimum bid price requirement. The company will reduce its total outstanding shares from approximately 52.6 million to around 1.3 million. Adjustments will also be made to stock options and incentive plans in line with the split.
Read more →-ISPC
Apr 9, 2026▼ -10.3%on this news· ran to -25% by day 3
iSpecimen achieves 85% Reduction in Human Biospecimen Shipping Time
iSpecimen has launched a new shipping model that reduces human biospecimen transit times by 70-85%, cutting delivery times down to as little as 1-2 days. This model eliminates the need for centralized hub processing and allows for direct shipments from supplier sites to customers globally. Enhanced partnerships in Europe and Eastern Europe facilitate access to rare biospecimens, while positive customer feedback emphasizes improved reliability and service quality following the changes.
Read more →-ISPC
Feb 6, 2026iSpecimen Achieves Rapid Procurement Milestone for Influenza Research
iSpecimen Inc. has achieved a significant milestone by rapidly procuring 500 influenza swab samples to support customer research. This accomplishment underscores the company's commitment to quality and responsiveness in sourcing human biospecimens. Additionally, iSpecimen continues to maintain a steady supply of cerebrospinal fluid and is seeing increased demand for various specimen types. Positive customer feedback highlights the reliability of their services.
Read more →-ISPC
Feb 6, 2026iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete
iSpecimen Inc. has successfully completed Milestone 2, which includes the integration of its SalesStack marketplace and the migration of legacy data. The new platform is now live and operational, enabling enhanced AI-driven matching between customer requests and supplier inventories. This achievement positions iSpecimen for future growth and operational efficiency.
Read more →-ISPC
Sep 4, 2025iSpecimen Approached by Crypto Currency Companies
iSpecimen Inc. has announced its strategic initiative to integrate digital assets into its business model, aiming to establish a corporate treasury reserve of up to $200 million using the Solana blockchain. Following this initiative, iSpecimen has received interest from several cryptocurrency companies concerning tokenized real-world assets. The CEO indicated a focus on diversifying the company's balance sheet while implementing treasury management strategies. However, the venture is subject to market volatility and regulatory uncertainties that could impact the company's growth prospects.
Read more →-ISPC
Aug 21, 2025▼ -29.8%on this news
iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform
iSpecimen Inc. has announced the successful completion of Milestone 1 in its digital transformation journey, powered by Salestack Solutions. This milestone involves enhancing the iSpecimen Marketplace's infrastructure, enabling improved operational efficiency and scalability. The completion is seen as a significant step towards creating a more efficient and secure marketplace, with future phases aimed at further integration and automation. CEO Robert Lim expressed optimism about unlocking greater efficiencies and enhancing marketplace capabilities as the company progresses.
Read more →-ISPC
Aug 7, 2025▲ +6.5%on this news· ran to -32% by day 3
iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow
iSpecimen has announced plans to build a corporate treasury of up to $200 million focusing on the Solana cryptocurrency, aiming to support long-term innovation and technology advancement. The initiative will involve partnerships with WestPark Capital and BlockArrow for advisory and management services, emphasizing security and compliance in handling digital assets. iSpecimen views this as a step towards financial and operational innovation, positioning itself as a leader in integrating blockchain technology within life sciences. The company aims to diversify its digital treasury across high-performing crypto assets with an initial focus on Solana.
Read more →-ISPC
Jul 31, 2025iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market
iSpecimen Inc. announced a private placement agreement with accredited investors, expected to yield approximately $1.75 million. The company will use the proceeds primarily for marketing and general corporate purposes. The offering is set to close around August 1, 2025, pending customary closing conditions. This funding aims to enhance iSpecimen's operations as it supports the research needs of scientists across various organizations.
Read more →-ISPC
Jul 24, 2025iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
iSpecimen Inc. has announced the pricing of a public offering for 5,714,283 shares of its common stock at $0.70 per share, aiming to raise approximately $4 million. The offering is set to close on July 25, 2025, pending customary closing conditions. The company plans to use the proceeds for marketing, initial payments to Sales Stack Solutions, and for working capital. The offering is being conducted on a firm commitment basis by WestPark Capital, Inc.
Read more →-ISPC
Jan 16, 2025▲ +8%on this news
iSpecimen Inc. Secures Suppliers for COVID-style hMPV Outbreak
iSpecimen Inc. has announced the acquisition of suppliers to handle a potential outbreak of human metapneumovirus (hMPV), which has been impacting hospitals in China. As hMPV spreads through respiratory droplets, it raises fears of a situation comparable to the COVID-19 pandemic. Currently, there is no vaccine for hMPV, emphasizing the vital need for high-quality biospecimens for research and vaccine development. iSpecimen aims to address this increasing demand through its global partnerships and advanced online marketplace for human biospecimens.
Read more →-ISPC
Dec 20, 2024iSpecimen will serve as a Preferred Provider of Cancer Biospecimens Woburn, MA
iSpecimen Inc. has announced strategic initiatives for 2025, positioning itself as a preferred provider of cancer biospecimens. The company plans to enhance access through new partnerships with U.S.-based cancer centers and establish a referral program with an international genomic sequencing partner. This will improve procurement efficiency for researchers and support advancements in cancer research. iSpecimen's data-driven strategies aim to streamline the specimen procurement process and expand its offerings, particularly in cancer-related biofluids.
Read more →-ISPC
Dec 13, 2024▼ -15.4%on this news
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
iSpecimen Inc. reported positive results from its Next Day Quote Program, designed to expedite the biospecimen pricing process for researchers. Launched in 2023, the program has demonstrated significant adoption, with 30% of sales opportunities and 48% of total quotes in November 2024 attributed to it. Senior Vice President Leslie Hoyt highlighted that swift quoting greatly increases the likelihood of purchase orders, underlining the program's effectiveness in meeting customer needs.
Read more →-ISPC
Dec 12, 2024iSpecimen Appoints Robert Lim as CEO and Director
iSpecimen Inc. has appointed Robert Lim as its new CEO and director. Lim has a background as the co-founder of a law firm and extensive experience in legal and marketing fields. His leadership is expected to foster innovative approaches for the company, enhancing operations and profitability in the biospecimen marketplace. iSpecimen connects researchers with healthcare providers to facilitate medical discovery through its online platform.
Read more →-ISPC
Sep 11, 2024iSpecimen Announces 1-for-20 Reverse Stock Split
iSpecimen Inc. announced a 1-for-20 reverse stock split of its common shares, effective September 13, 2024. The decision follows the approval from stockholders and aims to increase share price to attract institutional investors and meet Nasdaq listing requirements. The adjusted shares will trade under the same ticker symbol, ISPC. Broadridge Corporate Issuer Solutions will serve as the exchange agent for this stock split.
Read more →-ISPC
Aug 6, 2024iSpecimen Reports Second Quarter 2024 Results Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development
iSpecimen Inc. reported a substantial revenue increase of 76% year-over-year, reaching approximately $2.86 million for the second quarter of 2024, driven by higher specimen counts and an increase in average selling prices. The company also welcomed Brielan Smiechowski as the new Senior Vice President of Sales and Business Development. While costs have decreased significantly, iSpecimen still faced a net loss of approximately $2.11 million in the quarter. Overall, the company is focusing on improving operational efficiency and enhancing shareholder value.
Read more →About iSpecimen Inc.
Headquarters8 CABOT ROAD, WOBURN, MA, 08101
BIOPHARMAWATCH ELITE PLUS
Trade the next ISPC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime